Premium
Comparing Effects of Aminoguanidine and Metformin on Lowering Advanced Glycation Endproducts (AGEs) in STZ‐induced Diabetic Rats
Author(s) -
Zhao Chunsheng,
Zhang Yan,
Yang Jieying,
Tan Ningzhi,
Zhu JiaShi
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.578.14
Subject(s) - medicine , endocrinology , glycation , metformin , diabetes mellitus , streptozotocin , glucose tolerance test , insulin resistance
Literature reported aminoguanidine (AG) is effective in lowering AGEs and Metformin (MF) has been used for treating diabetes mellitus (DM). We have found in a companion study that plasma AGEs are elevated in STZ‐induced DM rats. In this study, we compared the AGEs‐lowering effects of AG (150 & 300 mg/kg) and MFH (500 mg/kg) by gavage for 12 wks in the STZ (i.p., 60mg/kg) DM rats. We found a 65% increase in plasma AGEs fluorescence (ex. 360nm, em. 450nm; 10755±3110) after received STZ, as compared to normal rats (6512±640; p<0.01). As compared to vehicle controls, plasma AGEs were decreased by 25% with 12‐wk of MFH (8015±2724, p<0.05), but no significant changes with AG (150 mg/kg: 10717±2202; or 300 mg/kg: 9411±2134) (p>0.20). AG (150 or 300 mg/kg) and MFH decreased fasting blood glucose (FBG) by 13%, 18% and 39%, and AUC of oral glucose tolerance test by 9%, 16% and 36% (p<0.01). In conclusion, MFH reduces plasma AGEs and FBG and improves glucose tolerance. AG at the current doses improves glucose metabolism, but higher doses of AG may be required to lower plasma AGEs in the STZ induced DM rats.